Peer-reviewed veterinary case report
Albendazole nanocrystals improve parasite treatment in dogs
By Paredes, Alejandro Javier et al.·Published in The Journal of pharmacy and pharmacology·2018·Unidad de Investigació·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A nanocrystal-based formulation improves the pharmacokinetic performance and therapeutic response of albendazole in dogs.
- Species:
- dog
Plain-English summary
A group of healthy dogs received a new nano-sized formulation of albendazole, a medication used to treat parasitic infections, to see if it worked better than a standard version. The study found that the new formulation was absorbed more effectively in the dogs' bodies and showed a significant reduction in the number of parasite eggs in their feces at a lower dose compared to the standard medication. Both formulations were effective at higher doses, but the new formulation proved to be more effective at a lower dose. This suggests that the nano-sized albendazole could be a better option for treating certain parasitic infections in dogs.
People also search for: dog parasite treatment · albendazole for dogs · dog worm medication effectiveness
Abstract
OBJECTIVES: Here, we aimed to assess the pharmacokinetic performance and therapeutic response (anthelmintic efficacy) of an albendazole (ABZ) nano-sized formulation in dogs. METHODS: In the pharmacokinetic study, ABZ self-dispersible nanocrystals (SDNCS) and a control formulation were administered orally to healthy dogs (n = 6). The concentrations of the sulphoxide metabolite in plasma were determined by high-performance liquid chromatography. For the anthelmintic efficacy trial, SDNCS and a commercially available formulation of ABZ were given to naturally parasitised dogs. The number of Ancylostoma caninum eggs in the faeces was determined using the McMaster technique. KEY FINDINGS: The area under the curve, Tmax and Cmax for the SDNCS were improved compared to the control. The efficacy study showed no statistical differences between the SDNCS and the commercial formulation at the doses of 25 and 12.5 mg/kg. However, significant differences (P < 0.05) between the treatments were found at 6.25 mg/kg (a quarter of the reference dose) with a reduction in the faecal nematode egg counts of 62.0 ± 21.1% and 100 ± 0% for the control and SDNCS, respectively. CONCLUSIONS: The improved pharmacokinetic performance observed for the novel formulation of ABZ correlated with an improved in vivo therapeutic response against a model intestinal nematode parasite in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29034951/